Bioscience Brands Limited reported unaudited consolidated earnings results for six months ended December 31, 2012. For the period, revenue was ZAR 8,365,634 compared to ZAR 12,235,205 in the same period last year. Operating loss was ZAR 18,705,345 compared to profit of ZAR 705,709 in the same period last year. Loss before taxation was ZAR 20,020,980 compared to ZAR 362,071 in the same period last year. Loss and comprehensive loss for the period was ZAR 16,364,278 compared to ZAR 222,026 in the same period last year. Cash flows from operating activities were ZAR 937,574 compared to cash flows used in operating activities of ZAR 1,675,747 in the same period last year. Loss per share basic and diluted was 0.55 cents compared to 0.01 cents in the same period last year.

BioScience Brands Limited provided earnings guidance for the six months ended December 31, 2012. The company announced that the loss per share and headline loss per shares for the six months ended 31 December 2012 are expected to be more than 20% worse than that of the previous interim period ended 31 December 2011. The company announced that the results for the six months ended 31 December 2012 are expected to be in the range of between 0.50 and 0.60 cents loss per share, and in the range of between 0.05 and 0.15 cents headline loss per share.

BioScience Brands Limited announced that they will report first half, 2013 results on Mar 28, 2013